SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- November 01, 2006 -- Novacea, Inc. (NASDAQ: NOVC) today announced that the company has made the strategic decision to focus on the development of Asentar™ (DN-101) and AQ4N (banoxantrone) and that it has notified Pierre Fabre Medicament, S.A of its decision to return the U.S. and Canadian development and commercialization rights of vinorelbine oral (OV).
